Adaptimmune Therapeutics plc (Nasdaq: ADAP)

Engel Law PLLC is investigating whether fair value to Adaptimmune shareholders will result from the proposed merger of Adaptimmune Therapeutics plc (Nasdaq: ADAP) with TCR² Therapeutics Inc., in which Adaptimmune will acquire all outstanding shares of TCR² common stock for 0.47233 shares of Adaptimmune for each TCR² share.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Adaptimmune Therapeutics plc

MM slash DD slash YYYY